Home
>
Pharmaceutical Intermediates
>
Bulk Drug Intermediates
>
Daclatasvir Dihydrochloride
for Sale
>
BMS-790052 dihydrochloride
BMS-790052 dihydrochloride
Unit Price:
Get Latest Price
CAS No.:
1009119-65-6
Content:
0.98%
Price valid (until):
2026-10-08
Company Type:
Manufactory
Location:
United States
Qualification:
Main Products:
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Product Description
-
Seller Information
-
Description
ProductName BMS-790052 dihydrochloride Cat No CEI-1257 Product Overview BMS-790052 is a potent inhibitor of HCV NS5A with EC50 value of 9-50 pM. NS5A (nonstructural protein 5A) is a zinc-binding protein and plays a pivotal role in HCV RNA replication. NS5A involves in mediating the host cell function and HCV infection, therefore, it is regarded as a promising target for HCV treatment. BMS-790052 is a selective HCV NS5A inhibitor and has the most potent ability to inhibit HCV replication reported so far. When using FRET assays to determine the efficiay of BMS-790052 on HCV NS5A, replicon cells were cultured in 96-well plates and after 12 hours BMS-790052 was added to test the replication activity and cytotoxicity, the results showed that the mean values of BMS-790052 for genotype 1a and 1b were 50 and 9 pM, respectively. In stable replication cell lines with GT-5a hybrid replicons (GT-5a-6, GT-5a-7, and GT-5a-9), BMS-790052 treatment showed effective antiviral activity with EC50 values range from 3 to 7 pM. It has been shown that oral administration of BMS-790052 was safe and well tolerated up to 200 mg when tested with healthy people, and it was safe and well tolerated at the dose of 100 mg when tested with HCV-infected patients. CAS No 1009119-65-6 Molecular Weight 811.8 Purity 0.98 Storage Store at -20°C Synonyms Daclatasvir dihydrochloride; BMS790052 dihydrochloride; BMS 790052 dihydrochloride Targets HCV NS5A Molecular Formula C40H52Cl2N8O6 Chemical Name dimethyl ((2S,2S)-((2S,2S)-2,2-(5,5-([1,1-biphenyl]-4,4-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate dihydrochloride Solubility Soluble in DMSO Shipping Conditions Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request category Bulk Drug Intermediates(c1112) cas_num 1009119-65-6 ECHEMI Editorial ReferenceDaclatasvir hydrochloride is a hydrochloride obtained by combining daclatasvir with two molar equivalents of hydrochloric acid. It is a potent inhibitor of nonstructural protein 5A and is used for treatment of hepatitis C. It has a role as an antiviral drug and a nonstructural protein 5A inhibitor. It contains a daclatasvir(2+).|Daclatasvir Dihydrochloride is the dihydrochloride salt form of daclatasvir, an orally available inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, with potential activity against HCV. Although the exact mechanism of action of daclatasvir has yet to be fully determined, this agent, upon oral administration and after intracellular uptake, appears to bind to domain I of the NS5A protein. This inhibits the activity of the NS5A protein and results in the disruption of the viral RNA replication complex, blockage of viral HCV RNA production, and inhibition of viral replication. NS5A, a zinc-binding and proline-rich hydrophilic phosphoprotein, plays a crucial role in HCV RNA replication. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family.
Daclatasvir dihydrochloride is a hepatitis C virus nonstructural 5A (NS5A) replication complex inhibitor which was first approved in Japan for the treatment of genotype 1 HCV patients who fail to respond to interferon plus ribavirin. The drug has also been approved for patients with untreated, chronic HCV who are eligible for interferon. Additionally, in Europe, daclatasvir was approved for use in combination with other products across genotype 1–4 HCV. Daclatasvir was discovered and developed by Bristol–Myers Squibb and a fascinating account describing the initiation of the program from a phenotypic screen and the medicinal chemistry strategy leading to the discovery of the compound has been recently reported.
Daclatasvir dihydrochloride is white to yellow powder. It is freely soluble in water (>700 mg/mL). The solubility is strongly pH-dependent and the solubility is high at low pH values.Basic Info-
Product Name:
Daclatasvir Dihydrochloride
Other Name:BMS 790052;BMS-790052;BMS790052 ;BMS 790052;DACLATASVIR;BMS-790052 DIHYDROCHLORIDE;BMS790052 DIHYDROCHLORIDE;BMS 790052 DIHYDROCHLORIDE;BMS-790052; BMS790052 ; BMS 790052;DACLATASVIR;Daclatasvir dihydrochloride (BMS-790052);BMS 790052 (di HClsalt);N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-;Daclatasvir dihydrochloride (BMS-790052 dihydrochloride);Dacatavir dihydrochloride
CAS No.:1009119-65-6
Molecular Formula:C40H51ClN8O6
InChIKeys:AQVSGTIFAZLGND-DDOLUWEFNA-N
Molecular Weight:775.35
Exact Mass:810.3386868
EC Number:816-965-3
UNII:50ZO25C11D
NCI Thesaurus Code:C166798
Color/Form:Off-White to Yellow
ATC Code:J05AP07
Categories:
Characteristics-
Melting Point:
>207°C (dec.)
Critical Temperature & Pressure:-20°C Freezer
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Location:
Shirley, New York 11967, USA
-
Payment Terms:
TT against copy of documents,D/P
-
Average lead Time:
15
-
Total Annual Revenue:
$1 million-$2.5 million
-
Year of Establishment:
2004
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product